• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性丙型肝炎患者抗病毒药物治疗智能监测系统(SiMON-VC)

Intelligent MONitoring System for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC).

作者信息

Margusino-Framiñán Luis, Cid-Silva Purificación, Mena-de-Cea Álvaro, Sanclaudio-Luhía Ana Isabel, Castro-Castro José Antonio, Vázquez-González Guillermo, Martín-Herranz Isabel

机构信息

Pharmacy Unit.A Coruña Universitary Hospital..

Internal Medicine Unit. A Coruña Universitary Hospital..

出版信息

Farm Hosp. 2017 Jan 1;41(n01):68-88. doi: 10.7399/fh.2017.41.1.10590.

DOI:10.7399/fh.2017.41.1.10590
PMID:28045653
Abstract

Two out of six strategic axes of pharmaceutical care in our hospital are quality and safety of care, and the incorporation of information technologies. Based on this, an information system was developed in the outpatient setting for pharmaceutical care of patients with chronic hepatitis C, SiMON-VC, which would improve the quality and safety of their pharmacotherapy. The objective of this paper is to describe requirements, structure and features of Si- MON-VC. Requirements demanded were that the information system would enter automatically all critical data from electronic clinical records at each of the visits to the Outpatient Pharmacy Unit, allowing the generation of events and alerts, documenting the pharmaceutical care provided, and allowing the use of data for research purposes. In order to meet these requirements, 5 sections were structured for each patient in SiMON-VC: Main Record, Events, Notes, Monitoring Graphs and Tables, and Follow-up. Each section presents a number of tabs with those coded data needed to monitor patients in the outpatient unit. The system automatically generates alerts for assisted prescription validation, efficacy and safety of using antivirals for the treatment of this disease. It features a completely versatile Indicator Control Panel, where temporary monitoring standards and alerts can be set. It allows the generation of reports, and their export to the electronic clinical record. It also allows data to be exported to the usual operating systems, through Big Data and Business Intelligence. Summing up, we can state that SiMON-VC improves the quality of pharmaceutical care provided in the outpatient pharmacy unit to patients with chronic hepatitis C, increasing the safety of antiviral therapy.

摘要

我院药学服务的六个战略轴心中有两个是医疗质量与安全以及信息技术的融入。基于此,我们开发了一个门诊环境下用于慢性丙型肝炎患者药学服务的信息系统SiMON-VC,它将提高患者药物治疗的质量与安全性。本文的目的是描述SiMON-VC的要求、结构和特点。所要求的是该信息系统能在每次门诊药房就诊时自动录入电子临床记录中的所有关键数据,允许生成事件和警报,记录所提供的药学服务,并允许将数据用于研究目的。为了满足这些要求,SiMON-VC为每个患者构建了5个部分:主记录、事件、注释、监测图表和表格以及随访。每个部分都有多个标签,包含在门诊科室监测患者所需的编码数据。该系统会自动生成辅助处方验证、使用抗病毒药物治疗该疾病的疗效和安全性方面的警报。它具有一个完全通用的指标控制面板,可在其中设置临时监测标准和警报。它允许生成报告并将其导出到电子临床记录中。它还允许通过大数据和商业智能将数据导出到常用操作系统中。总之,我们可以说SiMON-VC提高了门诊药房为慢性丙型肝炎患者提供的药学服务质量,提高了抗病毒治疗的安全性。

相似文献

1
Intelligent MONitoring System for antiviral pharmacotherapy in patients with chronic hepatitis C (SiMON-VC).慢性丙型肝炎患者抗病毒药物治疗智能监测系统(SiMON-VC)
Farm Hosp. 2017 Jan 1;41(n01):68-88. doi: 10.7399/fh.2017.41.1.10590.
2
Hepatitis C pharmacotherapy clinic.丙型肝炎药物治疗诊所。
Am J Health Syst Pharm. 2002 May 1;59(9):876. doi: 10.1093/ajhp/59.9.876a.
3
Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.口服直接抗病毒方案用于慢性丙型肝炎在实际生活条件下的安全性。
Postgrad Med. 2017 May;129(4):476-483. doi: 10.1080/00325481.2017.1311197. Epub 2017 Apr 10.
4
Efficacy and safety of a herbal mixture (Viron® tablets) in the treatment of patients with chronic hepatitis C virus infection: a prospective, randomized, open-label, proof-of-concept study.一种草药混合物(Viron®片)治疗慢性丙型肝炎病毒感染患者的疗效和安全性:一项前瞻性、随机、开放标签的概念验证研究。
Drug Des Devel Ther. 2015 Feb 11;9:799-804. doi: 10.2147/DDDT.S77168. eCollection 2015.
5
Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.退伍军人健康管理局的乙肝检测以及抗CD20抗体给药治疗。
World J Gastroenterol. 2016 May 21;22(19):4732-40. doi: 10.3748/wjg.v22.i19.4732.
6
Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1.通过治疗药物监测优化利巴韦林暴露量可改善1型慢性丙型肝炎患者的治疗反应。
Am J Gastroenterol. 2013 Jul;108(7):1176-8. doi: 10.1038/ajg.2013.140.
7
[Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].[特拉匹韦和博赛匹韦用于慢性丙型肝炎真实世界临床实践的成本效益及安全性]
Gastroenterol Hepatol. 2015 Dec;38(10):575-82. doi: 10.1016/j.gastrohep.2015.07.002. Epub 2015 Aug 28.
8
[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].[匈牙利慢性乙型和丙型病毒性肝炎抗病毒治疗经验(1998 - 2004年)]
Orv Hetil. 2007 May 6;148(18):819-26. doi: 10.1556/OH.2007.28114.
9
New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.慢性肾脏病、透析和移植患者丙型肝炎的新疗法。
Kidney Int. 2016 May;89(5):988-994. doi: 10.1016/j.kint.2016.01.011. Epub 2016 Mar 11.
10
Evaluation of rule effectiveness and positive predictive value of clinical rules in a Dutch clinical decision support system in daily hospital pharmacy practice.评估临床规则在荷兰临床决策支持系统中的有效性和阳性预测值在日常医院药学实践中的作用。
Artif Intell Med. 2013 Sep;59(1):15-21. doi: 10.1016/j.artmed.2013.04.001. Epub 2013 May 7.

引用本文的文献

1
Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus.药物相互作用对直接作用抗病毒药物治疗丙型肝炎病毒的疗效和安全性的影响。
Eur J Hosp Pharm. 2021 Jan;28(1):16-21. doi: 10.1136/ejhpharm-2019-001889. Epub 2019 Jun 13.
2
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.索磷布韦/维帕他韦±利巴韦林与格卡瑞韦/哌仑他韦治疗基因 3 型丙型肝炎病毒感染患者的疗效和安全性。
Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7.
3
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
在基因3型丙型肝炎病毒感染患者中,使用或不使用利巴韦林的达卡他韦/索磷布韦的有效性和安全性。真实临床实践中的结果。
Rev Esp Quimioter. 2019 Apr;32(2):137-144. Epub 2019 Feb 12.